Prevalence of Mycoplasma genitalium and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima Mycoplasma genitalium Assays for Diagnosis

Hilmarsdóttir, I.; Arnardóttir, Eva Mjöll; Jóhannesdóttir, Elísabet Reykdal; Valsdóttir, Freyja; Golparian, Daniel; Hadad, Ronza; Vigfússon, Hannes Bjarki; Unemo, Magnus

doi:10.1128/jcm.01084-20

Cited by 8 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…За последние годы наблюдается снижение эффектив ности препаратов данной группы, несмотря на различия в тактике назначения в разных странах. Случаи отсут ствия положительной динамики у пациентов после ре комендованных методов лечения были описаны иссле дователями в Европе, США и странах Азии [21][22][23]. В основе этой тревожной ситуации лежит несколько при чин: отсутствие международного консенсуса в отно шении стратегии обследования и лечения пациентов, необоснованное использование макролидов при респи раторных инфекциях, плохое соблюдение схем лечения пациентами и их партнерами, недостаточная доступ ность тестов для выявления устойчивости микоплазм, а также отсутствие мониторинга за распространением штаммов, несущих маркеры резистентности к антими кробным препаратам.…”

Section: Monitoring Of Macrolide Resistanceassociated Mutations In My...unclassified

Monitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia

Edelstein

Руднева

Romanov

et al. 2022

CMAC

View full text Add to dashboard Cite

Objective. To determine spectrum and prevalence of genetic determinants of resistance to macrolides in Mycoplasma genitalium in a Russian patient population. Materials and Methods. A total of 873 M. genitalium-positive samples from five geographical regions of Russia were investigated over the period of 2009–2019 using the previously developed protocol of real-time polymerase chain reaction (allows detecting any nucleotide substitutions in the 23S rRNA gene of M. genitalium at positions 2058, 2059, and 2611). The results were confirmed using Sanger sequencing. Results. The most frequent mutations associated with resistance to macrolides in M. genitalium were the following: A2058G (60.5%) and A2059G (30.2%). The relatively rare mutations were A2058T (7%) and C2611T (2.3%). In the studied period, there was no trend to increase in frequency of mutations associated with resistance to macrolides. The study results are presented as an open project on the AMRcloud platform (https://amrcloud.net/ru/project/demares/). Conclusions. Our data emphasize a need to introduce regular screening of M. genitalium-positive samples for the presence of macrolide resistance-associated mutations into clinical practice.

show abstract

Section: Monitoring Of Macrolide Resistanceassociated Mutations In My...unclassified

Monitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia

Edelstein

Руднева

Romanov

et al. 2022

CMAC

View full text Add to dashboard Cite

show abstract

“…В Европе уровень распространенности M. genitalium значительно варьирует. В Исландии в период с октября 2018 по январь 2019 г. частота выявления M. genitalium среди пациентов клиник составила 9,3%, причем среди мужчин она составила 7,7%, а среди женщин -10,9% [16]. В США в период с июня 2017 по июль 2018 г. среди мужчин с уретритом была показана частота выявления M. genitalium в 28,7%, при этом чаще это были афроамериканцы (79,8% против 66%), <30 лет (72,9% против 56,1%), а также те, кто заявлял только о гетеросексуальных связях (83,7% против 74,2%) [17] [20].…”

Section: эпидемиология M Genitalium распространенность M Genitaliumunclassified

“…nucleic acid amplification tests, NAAT) [6]. Также использование NAAT позволяет не только исследовать образец на присутствие M. genitalium, но и одновременно определять мутации, вызывающие резистентность к различным классам антимикробных препаратов [16,[53][54][55]. На данный момент существуют не только большое количество разнообразных протоколов, описанных в научных исследованиях, но также и коммерчески доступные наборы реагентов для проведения анализа в клинической практике.…”

Section: методы молекулярной диагностики M Genitalium амплификация нуклеиновых кислотunclassified

“…Для образцов, полученных от мужчин, специфичность составила 100%, в то время как для женских мазков она составила 99,5%, а для образцов женской мочи -100% [58]. Для тест-системы S-DiaMGTV (Diagenode, Бельгия) чувствительность составила 72,5%, а специфичность -99,9% [16]. Для тест-системы N. gonorrhoeae/ C. trachomatis/M.…”

Section: полимеразная цепная реакцияunclassified

See 1 more Smart Citation

Molecular epidemiology and antimicrobials resistance mechanism of Mycoplasma genitlaium

Shedko

Дмитриевна²,

Головешкина

et al. 2021

Vestnik dermatologii i venerologii

View full text Add to dashboard Cite

Currently, infections caused by Mycoplasma genitalium are ones the most common sexually transmitted infections. Their prevalence is varied from 1.3% to 15.9%. Infections caused by M.genitalium may lead to urethritis in men and a wide spectrum of diseases in women. Antibiotic resistance now is one of the most emerging problems both in the scientific and in the healthcare fields. The usage of antimicrobials inhibiting cell wall synthesis for the treatment of M.genitalium is ineffective, and resistance to macrolides and fluoroquinolones is increasing rapidly. M.genitalium infections diagnostics is complicated due to specific conditions and duration of culture methods. The usage of nucleic acid amplification techniques is the most relevant for laboratory diagnostics, and is used in existing assays. This review compiles current data on the prevalence, molecular mechanisms of pathogenesis and antibiotic resistance, as well as diagnostics methods of M.genitalium.

show abstract

“…At the WHO CC, Sweden, MRAMs were identified using the ResistancePlus MG kit (SpeeDx Pty. Ltd., NSW, Australia;Tabrizi et al, 2017 Roy et al, 2020) and QRAMs detected with PCR amplification of a 220 bp region of MG parC followed by Sanger sequencing, using previously described method (Shipitsyna et al, 2017;Hadad et al, 2018;Unemo et al, 2018;Hilmarsdóttir et al, 2020) and PCR primers (Deguchi et al, 2001;Shimada et al, 2010). At the NICD, South Africa, MRAMs were identified using PCR amplification of a 147 bp region of the MG 23S rRNA gene followed by Sanger sequencing using previously described primers (Jensen et al, 2008), and methods (Muller et al, 2019;Mahlangu et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Mycoplasma genitalium prevalence, antimicrobial resistance-associated mutations, and coinfections with non-viral sexually transmitted infections in high-risk populations in Guatemala, Malta, Morocco, Peru and South Africa, 2019–2021

Shipitsyna

Kularatne²,

Golparian³

et al. 2023

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

The prevalence of Mycoplasma genitalium (MG) and MG antimicrobial resistance (AMR) appear to be high internationally, however, prevalence data remain lacking globally. We evaluated the prevalence of MG and MG AMR-associated mutations in men who have sex with men (MSM) in Malta and Peru and women at-risk for sexually transmitted infections in Guatemala, South Africa, and Morocco; five countries in four WHO regions mostly lacking MG prevalence and AMR data, and estimated MG coinfections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV). Male urine and anorectal samples, and vaginal samples were tested for MG, CT, NG, and TV (only vaginal samples) using Aptima assays (Hologic). AMR-associated mutations in the MG 23S rRNA gene and parC gene were identified using ResistancePlus MG kit (SpeeDx) or Sanger sequencing. In total, 1,425 MSM and 1,398 women at-risk were recruited. MG was detected in 14.7% of MSM (10.0% in Malta and 20.0% Peru) and in 19.1% of women at-risk (12.4% in Guatemala, 16.0% Morocco, 22.1% South Africa). The prevalence of 23S rRNA and parC mutations among MSM was 68.1 and 29.0% (Malta), and 65.9 and 5.6% (Peru), respectively. Among women at-risk, 23S rRNA and parC mutations were revealed in 4.8 and 0% (Guatemala), 11.6 and 6.7% (Morocco), and 2.4 and 3.7% (South Africa), respectively. CT was the most frequent single coinfection with MG (in 2.6% of MSM and 4.5% of women at-risk), compared to NG + MG found in 1.3 and 1.0%, respectively, and TV + MG detected in 2.8% of women at-risk. In conclusion, MG is prevalent worldwide and enhanced aetiological MG diagnosis, linked to clinical routine detection of 23S rRNA mutations, in symptomatic patients should be implemented, where feasible. Surveillance of MG AMR and treatment outcome would be exceedingly valuable, nationally and internationally. High levels of AMR in MSM support avoiding screening for and treatment of MG in asymptomatic MSM and general population. Ultimately, novel therapeutic antimicrobials and/or strategies, such as resistance-guided sequential therapy, and ideally an effective MG vaccine are essential.

show abstract

Prevalence of Mycoplasma genitalium and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima Mycoplasma genitalium Assays for Diagnosis

Cited by 8 publications

References 28 publications

Monitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia

Monitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia

Molecular epidemiology and antimicrobials resistance mechanism of Mycoplasma genitlaium

Mycoplasma genitalium prevalence, antimicrobial resistance-associated mutations, and coinfections with non-viral sexually transmitted infections in high-risk populations in Guatemala, Malta, Morocco, Peru and South Africa, 2019–2021

Contact Info

Product

Resources

About